Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy

Helgason, G.V. , Mukhopadhyay, A., Karvela, M., Salomoni, P., Calabretta, B. and Holyoake, T.L. (2013) Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. Current Cancer Drug Targets, 13(7), pp. 724-34.

Full text not currently available from Enlighten.

Publisher's URL: http://www.benthamscience.com/cdt/

Abstract

The insensitivity of Chronic Myeloid Leukaemia (CML) stem cells to Tyrosine Kinase Inhibitor (TKI) treatment is now believed to be the main reason for disease persistence experienced in patients. It has been shown that autophagy, an evolutionarily conserved catabolic process that involves degradation of unnecessary or harmful cellular components via lysosomes, is induced following TKI treatment in CML cells. Of clinical importance, autophagy inhibition, using the anti-malarial drug hydroxychloroquine (HCQ), sensitised CML cells, including primitive CML stem cells, to TKI treatment. In this review we discuss the role of autophagy in the maintenance and survival of stem cells in more detail, with a focus on its role in survival of CML stem cells and the possibility to inhibit this pathway as a way to eliminate persistent CML stem cells in vitro and in patients.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Holyoake, Professor Tessa and Mukhopadhyay, Dr Arunima and Helgason, Professor Vignir and Karvela, Miss Maria
Authors: Helgason, G.V., Mukhopadhyay, A., Karvela, M., Salomoni, P., Calabretta, B., and Holyoake, T.L.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Current Cancer Drug Targets
ISSN:1568-0096
ISSN (Online):1873-5576

University Staff: Request a correction | Enlighten Editors: Update this record